Perrigo Company (PRGO) 92.07 $PRGO
Look for Shares of Perrigo to Potentially Pullback after Yesterday's 3.01% Rise
Comtex SmarTrend(R) - Tue Sep 06, 1:52PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $90.93 to a high of $94.74. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $92.06 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 92.07 (+1.32)
Perrigo Announces Tentative FDA Approval For Generic Version Of Epiduo® Gel
PR Newswire - Thu Sep 01, 8:01AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%).
PRGO: 92.07 (+1.32)
Look for Shares of Perrigo to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Tue Aug 30, 2:09PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $88.87 to a high of $91.17. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $89.93 on volume of 594,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 92.07 (+1.32)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 239.12 (+3.16), GNRX: 24.86 (+0.46), PRGO: 92.07 (+1.32), AXGN: 8.94 (+0.05), AKRX: 26.46 (-0.01), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), AMPH: 18.91 (+0.35), NVS: 80.15 (+0.77)
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel
PR Newswire - Tue Aug 23, 8:10AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA"
for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016 were $178 million.
PRGO: 92.07 (+1.32)
Post Earnings Coverage as Perrigo Doubles Profit
ACCESSWIRE - Mon Aug 15, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 15, 2016 / Active Wall St. announces its post-earnings coverage on Perrigo Company PLC (NYSE: PRGO). The company announced its second quarter fiscal 2016 results on August 10, 2016. The over-the-counter drug specialist doubled its profit. However, the company slashed its full-year earnings forecast for the second time in 2016, citing pricing pressure in its generic drugs business. Register with us now for your free membership at: http://www.activewallst.com/register/.
BIIB: 310.67 (-2.92), VRX: 29.47 (+0.71), PRGO: 92.07 (+1.32), MYL: 40.40 (+0.43), VRX.TO: 37.86 (+0.52)
Downgrade Alert for Perrigo (PRGO)
Comtex SmarTrend(R) - Fri Aug 12, 3:19AM CDT
Perrigo (NASDAQ RGO) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $85.80 on volume of 5.9 million shares, above average daily volume of 3.3 million. Perrigo Company manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company's customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson's, CVS, and Target, and major wholesalers such as Super Valu and McKesson.
PRGO: 92.07 (+1.32)
Stock Market News for August 11, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 9:10AM CDT
Benchmarks ended in the red on Wednesday following a decline in crude prices after the EIA reported an increase in U.S. crude inventories last week
PRGO: 92.07 (+1.32), DO: 16.40 (+0.12), SE: 41.00 (+4.85), RIG: 9.92 (+0.29), DIS: 93.80 (-0.62), XOM: 88.57 (+1.15), APA: 51.67 (+0.38), JD: 26.54 (+0.99), MRO: 15.64 (+0.15), CVX: 102.43 (+1.50)
After Yesterday's Decline of 9.93%, Perrigo Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 10, 11:48AM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $82.50 to a high of $86.70. Yesterday, the shares fell 9.9%, which took the trading range below the 3-day low of $91.68 on volume of 9.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRGO: 92.07 (+1.32)
Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 9:49AM CDT
Perrigo Company's (PRGO) second-quarter 2016 earnings of $1.93 per share fell short of expectations while the company lowered the outlook for the same.
BIIB: 310.67 (-2.92), PRGO: 92.07 (+1.32), ANIP: 61.55 (+1.69), CORT: 5.48 (+0.17)
Perrigo (PRGO) Misses on Q2 Earnings, Lowers View
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 5:57AM CDT
Perrigo (PRGO) failed to beat on second-quarter 2016 earnings.
PRGO: 92.07 (+1.32)
Perrigo Company plc Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 10, 5:29AM CDT
-- Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses*
PRGO: 92.07 (+1.32)
NVIDIA, TransCanada Corporation, Skechers, Apache Corporation, and Perrigo Co. and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Aug 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for APA, NVDA, PRGO, SKX, and TRP.
PRGO: 92.07 (+1.32), TRP: 46.23 (-0.46), SKX: 24.30 (-0.07), APA: 51.67 (+0.38), NVDA: 63.12 (+0.59)
Medical Products' Earnings on Aug 10: PRGO, NVTR & BSGM
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:32AM CDT
The scorecard has so far exhibited a 4.1% year-over-year decline in second-quarter earnings on 0.9% lower revenues.
PRGO: 92.07 (+1.32), NVTR: 6.84 (-0.10)
Perrigo (PRGO) Q2 Earnings: Stock Likely to Disappoint?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:25AM CDT
Perrigo Company (PRGO) is set to report second-quarter 2016 results on Aug 10. It recorded a positive earnings surprise of 1.16% last quarter.
PRGO: 92.07 (+1.32), ADHD: 4.84 (+0.07), MCRB: 10.68 (+0.55), IONS: 29.37 (-0.09)
Perrigo Completes The Divestiture Of Its Vitamins, Minerals & Supplements Business To IVC
PR Newswire - Mon Aug 08, 7:12AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC).
PRGO: 92.07 (+1.32)
Perrigo Set to Possibly Pullback After Yesterday's Rally of 2.64%
Comtex SmarTrend(R) - Wed Aug 03, 2:20PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $90.79 to a high of $94.12. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $91.87 on volume of 542,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 92.07 (+1.32)
Perrigo Company plc Announces Quarterly Dividend
PR Newswire - Tue Aug 02, 10:59AM CDT
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on August 26, 2016.
PRGO: 92.07 (+1.32)
Research Report on These Healthcare Sector Equities -- Valeant Pharma, Pernix Therapeutics, Perrigo, and Lipocine
PR Newswire - Mon Aug 01, 6:35AM CDT
The number of individuals who require medical attention and treatment is constantly growing, which is why Healthcare stocks remain in high demand. Earnings growth potential within the healthcare sector is much higher compared with other sectors, opening long-term opportunities for investors. Stock-Callers.com reviews the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Perrigo Co. PLC (NYSE: PRGO), and Lipocine Inc. (NASDAQ: LPCN). Learn more about these stocks by accessing their free research reports at:
PRGO: 92.07 (+1.32), VRX: 29.47 (+0.71), PTX: 0.56 (-0.03), LPCN: 3.39 (-0.09), VRX.TO: 37.86 (+0.52)
Look for Shares of Perrigo to Potentially Pullback after Yesterday's 3.01% Rise
Comtex SmarTrend(R) - Tue Sep 06, 1:52PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $90.93 to a high of $94.74. Yesterday, the shares gained 3.0%, which took the trading range above the 3-day high of $92.06 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 92.07 (+1.32)
Perrigo Announces Tentative FDA Approval For Generic Version Of Epiduo® Gel
PR Newswire - Thu Sep 01, 8:01AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Epiduo® Gel (adapalene and benzoyl peroxide 0.1%/2.5%).
PRGO: 92.07 (+1.32)
Look for Shares of Perrigo to Potentially Pullback after Yesterday's 2.12% Rise
Comtex SmarTrend(R) - Tue Aug 30, 2:09PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $88.87 to a high of $91.17. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $89.93 on volume of 594,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 92.07 (+1.32)
Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 239.12 (+3.16), GNRX: 24.86 (+0.46), PRGO: 92.07 (+1.32), AXGN: 8.94 (+0.05), AKRX: 26.46 (-0.01), MYL: 40.40 (+0.43), TEVA: 51.33 (+0.11), AMPH: 18.91 (+0.35), NVS: 80.15 (+0.77)
Perrigo Announces Tentative FDA Approval For Generic Version Of Suprep® Oral Solution And Confirms Patent Challenge For Generic Version Of Mirvaso® Gel
PR Newswire - Tue Aug 23, 8:10AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced it has received tentative approval from the U.S. Food and Drug Administration ("FDA"
for the generic version of Suprep® (sodium sulfate/potassium sulfate/magnesium sulfate) oral solution. The drug is indicated for the treatment of cleansing of the colon in preparation for colonoscopy in adults. Annual sales for the past 12 months ending July 2016 were $178 million. PRGO: 92.07 (+1.32)
Post Earnings Coverage as Perrigo Doubles Profit
ACCESSWIRE - Mon Aug 15, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 15, 2016 / Active Wall St. announces its post-earnings coverage on Perrigo Company PLC (NYSE: PRGO). The company announced its second quarter fiscal 2016 results on August 10, 2016. The over-the-counter drug specialist doubled its profit. However, the company slashed its full-year earnings forecast for the second time in 2016, citing pricing pressure in its generic drugs business. Register with us now for your free membership at: http://www.activewallst.com/register/.
BIIB: 310.67 (-2.92), VRX: 29.47 (+0.71), PRGO: 92.07 (+1.32), MYL: 40.40 (+0.43), VRX.TO: 37.86 (+0.52)
Downgrade Alert for Perrigo (PRGO)
Comtex SmarTrend(R) - Fri Aug 12, 3:19AM CDT
Perrigo (NASDAQ
RGO) was downgraded from Outperform to Market Perform at Northland today. The stock closed yesterday at $85.80 on volume of 5.9 million shares, above average daily volume of 3.3 million. Perrigo Company manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company's customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson's, CVS, and Target, and major wholesalers such as Super Valu and McKesson. PRGO: 92.07 (+1.32)
Stock Market News for August 11, 2016
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 9:10AM CDT
Benchmarks ended in the red on Wednesday following a decline in crude prices after the EIA reported an increase in U.S. crude inventories last week
PRGO: 92.07 (+1.32), DO: 16.40 (+0.12), SE: 41.00 (+4.85), RIG: 9.92 (+0.29), DIS: 93.80 (-0.62), XOM: 88.57 (+1.15), APA: 51.67 (+0.38), JD: 26.54 (+0.99), MRO: 15.64 (+0.15), CVX: 102.43 (+1.50)
After Yesterday's Decline of 9.93%, Perrigo Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 10, 11:48AM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $82.50 to a high of $86.70. Yesterday, the shares fell 9.9%, which took the trading range below the 3-day low of $91.68 on volume of 9.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PRGO: 92.07 (+1.32)
Perrigo (PRGO) Misses Q2 Earnings Estimates, Cuts '16 View
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 9:49AM CDT
Perrigo Company's (PRGO) second-quarter 2016 earnings of $1.93 per share fell short of expectations while the company lowered the outlook for the same.
BIIB: 310.67 (-2.92), PRGO: 92.07 (+1.32), ANIP: 61.55 (+1.69), CORT: 5.48 (+0.17)
Perrigo (PRGO) Misses on Q2 Earnings, Lowers View
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 5:57AM CDT
Perrigo (PRGO) failed to beat on second-quarter 2016 earnings.
PRGO: 92.07 (+1.32)
Perrigo Company plc Reports Second Quarter 2016 Financial Results
PR Newswire - Wed Aug 10, 5:29AM CDT
-- Delivered second quarter reported (GAAP) net sales of $1.48 billion and adjusted (non-GAAP) net sales of $1.44 billion, excluding sales of $44 million from held-for-sale businesses*
PRGO: 92.07 (+1.32)
NVIDIA, TransCanada Corporation, Skechers, Apache Corporation, and Perrigo Co. and more offer option-trading opportunities that offer returns of more than 20%
PR Newswire - Tue Aug 09, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for APA, NVDA, PRGO, SKX, and TRP.
PRGO: 92.07 (+1.32), TRP: 46.23 (-0.46), SKX: 24.30 (-0.07), APA: 51.67 (+0.38), NVDA: 63.12 (+0.59)
Medical Products' Earnings on Aug 10: PRGO, NVTR & BSGM
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 7:32AM CDT
The scorecard has so far exhibited a 4.1% year-over-year decline in second-quarter earnings on 0.9% lower revenues.
PRGO: 92.07 (+1.32), NVTR: 6.84 (-0.10)
Perrigo (PRGO) Q2 Earnings: Stock Likely to Disappoint?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:25AM CDT
Perrigo Company (PRGO) is set to report second-quarter 2016 results on Aug 10. It recorded a positive earnings surprise of 1.16% last quarter.
PRGO: 92.07 (+1.32), ADHD: 4.84 (+0.07), MCRB: 10.68 (+0.55), IONS: 29.37 (-0.09)
Perrigo Completes The Divestiture Of Its Vitamins, Minerals & Supplements Business To IVC
PR Newswire - Mon Aug 08, 7:12AM CDT
Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has completed the previously announced divestiture of its U.S. Vitamins, Minerals & Supplements (VMS) business to International Vitamin Corporation (IVC).
PRGO: 92.07 (+1.32)
Perrigo Set to Possibly Pullback After Yesterday's Rally of 2.64%
Comtex SmarTrend(R) - Wed Aug 03, 2:20PM CDT
Perrigo (NASDAQ
RGO) traded in a range yesterday that spanned from a low of $90.79 to a high of $94.12. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $91.87 on volume of 542,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. PRGO: 92.07 (+1.32)
Perrigo Company plc Announces Quarterly Dividend
PR Newswire - Tue Aug 02, 10:59AM CDT
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.145 per share, payable on September 13, 2016 to shareholders of record on August 26, 2016.
PRGO: 92.07 (+1.32)
Research Report on These Healthcare Sector Equities -- Valeant Pharma, Pernix Therapeutics, Perrigo, and Lipocine
PR Newswire - Mon Aug 01, 6:35AM CDT
The number of individuals who require medical attention and treatment is constantly growing, which is why Healthcare stocks remain in high demand. Earnings growth potential within the healthcare sector is much higher compared with other sectors, opening long-term opportunities for investors. Stock-Callers.com reviews the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), Perrigo Co. PLC (NYSE: PRGO), and Lipocine Inc. (NASDAQ: LPCN). Learn more about these stocks by accessing their free research reports at:
PRGO: 92.07 (+1.32), VRX: 29.47 (+0.71), PTX: 0.56 (-0.03), LPCN: 3.39 (-0.09), VRX.TO: 37.86 (+0.52)
